$3.12
▲ +2.3% Today
as of Jul 22, 16:50 ET
Last 30 days
Recent Press Releases & News
Opus Genetics Provides BEST1 Program Update with Detailed Timeline for OPGx-BEST1 Results
Opus Genetics Unlocks Key Milestone With US FDA Alignment on OPGx-LCA5 Phase 3, Wedbush Says
Opus Genetics Announces FDA Alignment on Phase 3 Registrational Trial Design for OPGx-LCA5 in LCA5-Associated Inherited Retinal Disease
Overview
52-week range
$0.90
$5.81
45% of range
Avg surprise (last 3)
-103.6%
Avg reaction (last 2)
+0.6%
50% positive
Latest IV / EM
736%
EM ±168.3% · $3 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue May 12, 2026 | Mar/2026 | $-0.75 | $-0.16 | -368.8% | -134.4% | +1.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.25 | — | — | — | — | financials |
| Wed Aug 13, 2025 | Jun/2025 | $-0.12 | $-0.25 | +52.0% | — | — | earnings |
| Thu May 15, 2025 | Mar/2025 | $-0.32 | $-0.34 | +5.9% | — | 0.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.29 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.30 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.29 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.25 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.24 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 12, 2026 | Jun/2026 | OTHER | -$0.15 | -$0.12 | -25.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-14M | — | $-8M | $-9M | $-10M | — | $-8M | $-8M |
| Net income | $-66M | — | $-17M | $-7M | $-8M | — | $-8M | $-8M |
| EPS (diluted) | $-0.75 | — | $-0.25 | $-0.12 | $-0.24 | — | $-0.29 | $-0.30 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $60M | $45M | $31M | $32M | $42M | $30M | $37M | $41M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $67M | $50M | $36M | $38M | $48M | $37M | $40M | $45M |
| Total assets | $67M | $50M | $36M | $39M | $48M | $37M | $40M | $45M |
| Long-term debt | $1M | $1M | $1M | $1M | — | $0 | — | — |
| Total liabilities | $88M | $35M | $30M | $21M | $24M | $11M | $6M | $4M |
| Total equity | $-46M | $15M | $6M | $17M | $5M | $7M | $34M | $41M |